The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study

• Egile Nagusiak: Pasquale Pignatelli (Egilea), Francesco Baratta (Egilea), Raffaella Buzzetti (Egilea), Alessandra D'Amico (Egilea), Valentina Castellani (Egilea), Simona Bartimoccia (Egilea), Antonio Siena (Egilea), Luca D'Onofrio (Egilea), Ernesto Maddaloni (Egilea), Annachiara Pingitore (Egilea), Giovanni Alfonso Chiariello (Egilea), Francesca Santilli (Egilea), Daniele Pastori (Egilea), Nicholas Cocomello (Egilea), Francesco Violi (Egilea), Maria Del Ben (Egilea), Vittoria Cammisotto (Egilea), Roberto Carnevale (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Sodium-glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozi...